HR 6417 amends the existing "Ending Importation of Russian Oil Act" to ban imports of energy products (classified under Harmonized Tariff Schedule chapter 27) produced at any refinery using crude oil originating in Russia. This directly affects U.S. importers and companies bringing in such refined petroleum products. The key provision prohibits these imports regardless of where the refinery is located, targeting oil that has been "laundered" through foreign processing. The bill updates the existing law by adding this origin-based import ban as a new section.
This bill requires states to submit annual lists of individuals convicted of sexually violent offenses who have been deemed "sexually dangerous" under existing law. It directs the Attorney General to review these lists to determine if federal prosecution is warranted for those individuals. The bill also restricts Medicaid and Medicare benefits for these "specified individuals," with an exception for those receiving involuntary inpatient treatment in hospitals or skilled nursing facilities. These provisions apply specifically to people meeting the defined criteria under the Adam Walsh Act.
The ARCC Act provides $100 million in federal funding to help apprentices and pre-apprentices in job training programs cover childcare costs. It authorizes competitive grants to 10 states, which must distribute monthly stipends of at least $500 per dependent child directly to eligible childcare providers on behalf of participants in these programs. The bill prioritizes individuals from historically underrepresented groups (based on race, ethnicity, or gender) and ensures stipends are tax-free while not affecting eligibility for other federal benefits. States must report on participation, program completion rates, and demographic data, with the Secretary later summarizing program impacts for Congress.
HR 6283, the DRUG Act, regulates pharmacy benefit managers (PBMs) to prevent practices that may increase prescription drug costs for consumers. The bill prohibits PBMs from earning revenue based on drug prices or discounts, requiring them to charge flat dollar service fees instead of fees tied to drug costs. It bans PBMs from steering patients to pharmacies they own or control, mandates equal reimbursement for affiliated and non-affiliated pharmacies, and prohibits charging different fees for the same drug. These provisions apply to group health plans, health insurance issuers, and PBMs, with enforcement beginning for plan years starting January 1, 2026. Violations would result in $10,000 daily penalties and require disgorgement of improperly received payments.
This bill requires Medicare to use the most recent, accurate data when calculating geographic payment adjustments for physicians, directly affecting doctors who treat Medicare patients. It specifically mandates using current physician wage data instead of non-physician wage data as a proxy, and requires updated office rent or health center expense data for practice cost calculations. The bill also establishes minimum payment floors for 2024 and beyond, preventing budget-neutral reductions in physician reimbursement rates. These changes aim to better reflect current costs for delivering care in different areas.
The Maximum Pressure Act (HR 6114) is a legislative proposal that would maintain and expand U.S. sanctions against Iran. The bill would codify existing sanctions, require Iran to meet 12 specific conditions before sanctions could be lifted (including ending support for terrorism, releasing hostages, and ending nuclear enrichment), and expand sanctions on Iran's Revolutionary Guard Corps and missile programs. It also establishes new reporting requirements for the U.S. government to monitor Iran's activities and the impact of sanctions. The legislation would require congressional review before any sanctions could be lifted or modified, preventing the executive branch from unilaterally easing restrictions.
This bill amends Medicare, Medicaid, and private insurance rules to improve coverage for drugs treating rare diseases (defined as conditions affecting 200,000 or fewer people in the U.S.). It requires coverage for rare disease drug uses supported by peer-reviewed medical literature and not listed as contraindicated in FDA labeling or medical reference guides. Private insurers must provide expedited review processes for denials of such drugs. The changes apply 30 days after enactment, affecting insurers and patients seeking coverage for rare disease treatments.
HR 6020, the Honor Our Living Donors Act, amends federal law to ensure living organ donors are fully reimbursed for qualifying expenses without considering the recipient's income. It prohibits organ recipients from having their income factored into reimbursement calculations and requires the Secretary to annually report whether current funding covers all donor expenses, including estimates of unmet needs. This bill directly affects living organ donors and the federal reimbursement program under the Public Health Service Act.
The Revoke Iranian Funding Act of 2023 would cancel all existing U.S. licenses and exemptions allowing funds to be released to Iran for humanitarian purposes, including a $6 billion transfer from South Korea. It also rescinds a specific waiver issued in September 2023 that permitted such transfers. The bill requires the Treasury to submit a 30-day report to Congress detailing Iranian assets blocked by the U.S. and current sanctions exemptions related to Iran. This legislation directly restricts U.S. financial access for Iran and its designated entities, aiming to prevent funds from being diverted to support terrorism.
This bill, titled "Freezing HAMAS Act" (though it concerns Iran sanctions, not Hamas), reinstates U.S. sanctions on Iran that were previously waived or suspended under agreements with Iran. It specifically targets sanctions from the 2012 Iran Freedom and Counter-Proliferation Act and the 2012 National Defense Authorization Act, including a September 2023 waiver related to fund transfers. The bill prohibits the U.S. government from releasing funds or assets to Iran or granting further waivers related to these sanctions. It directly affects U.S. government actions regarding Iran financial transactions and enforcement of existing sanctions.
HR 5819, the COMPLETE Care Act, incentivizes Medicare primary care providers to integrate behavioral health services by increasing payments for specific services (like mental health and substance use disorder support) during 2025-2027. Providers using designated HCPCS codes for integrated care would receive 125-175% of standard payment rates, with the percentage declining annually. The bill also requires these providers to report on integration quality measures and mandates technical assistance for practices adopting integrated models, funded through new appropriations for 2024-2027. It directly affects Medicare-participating primary care practices serving beneficiaries needing mental health or substance use services.
This bill expands Medicare coverage for in-home administration of intravenous immune globulin (IVIG) to include treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), effective January 1, 2026. It amends Medicare law to add these conditions to the list of covered primary immune deficiency diseases, directly affecting Medicare beneficiaries with CIDP or MMN who currently lack coverage for in-home IVIG. The bill also allows Medicare payment adjustments based on whether IVIG is used for primary immune deficiency or these new neurological conditions, as determined by the Secretary through formal rulemaking. This creates a specific policy change to broaden access for two neurological conditions previously excluded from in-home IVIG coverage.
